Bottom line
Is IDNA a good fund? The bottom line
IDNA is a managed health care sector ETF from iShares.
It charges 0.47% — about $47 a year on every $10,000 invested, cheaper than 83% of health care sector funds we track.
It returned −1.0% over one year, −4.8% a year over five years (as of Dec 31, 2024, per its prospectus).
With $191 million in net assets and 61 holdings, its largest position is BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares (10.4%) and the top 10 make up 49.5% of the portfolio.
What stands out
- Low cost: cheaper than 83% of health care sector peers
What to watch
- 5-year return in the bottom quarter of its category
Updated Nov 19, 2026
What IDNA invests in
The iShares Genomics Immunology and Healthcare ETF (the Fund ) seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering.
The Fund seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma Index ? (the Underlying Index ), which measures the performance of equity securities issued by companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determined by ICE Data Indices, LLC or its affiliates (the Index Provider or IDI ). The Underlying Index is composed of equity securities primarily listed in one of 42 developed and emerging market countries. Companies must have equal to or greater than 50% of their revenue from one or more selected Level 6 industries, as defined by the FactSet Revere Business Industry Classification System ( RBICS ), which includes biopharmaceutical industries, healthcare equipment industries, and healthcare services…
From the fund's prospectus (filed Nov 21, 2025).
IDNA performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| IDNA | −1.0% | −4.8% | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2024
What IDNA costs
On a $10,000 investment, IDNA's 0.47% expense ratio costs about $47 a year. The prospectus estimates $591 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
IDNA top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 10.39% |
| 2 | Bayer Aktiengesellschaft | 4.81% |
| 3 | Twist Bioscience Corp | 4.79% |
| 4 | Revolution Medicines, Inc. | 4.55% |
| 5 | Regeneron Pharmaceuticals, Inc. | 4.35% |
| 6 | Genmab A/s | 4.23% |
| 7 | Incyte Corporation | 4.23% |
| 8 | Moderna, Inc. | 4.19% |
| 9 | Takeda Pharmaceutical Company Limited | 4.05% |
| 10 | Merck & Co., Inc. | 3.91% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 49.5% of the fund. See all top 25 holdings and asset mix →